Correction to ‘Pharmacovigilance study of <scp>INSTIs</scp> associated with weight gain and glucose/lipid metabolism adverse events based on the <scp>FDA</scp> adverse event reporting system’

Zhang, L, Chen, L, Tang, J, et al. Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system. HIV Med. 2026; 27(5): 749–760. doi:10.1111/hiv.70205 In the version of this article initially published, the funding information was incomplete. The correct version is as follows: The author(s) declare that financial support was received for the research and/or publication of this article. This study was funded by the Special Research Fund for the Central High-level Hospitals of Peking Union Medical College Hospital (2022-PUMCH-D-008), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2021-I2M-1-037), the National Key Technologies R&D Program for the 13th Five-year Plan (2017ZX10202101-001), the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) (2025-12M-XHZY-002) and the Peking Union Medical College Hospital Talent Cultivation Program (Category A) (ULJ03044). We apologize for this error.